ATE374777T1 - Analoga als antitumorale verbindungen - Google Patents

Analoga als antitumorale verbindungen

Info

Publication number
ATE374777T1
ATE374777T1 AT02753134T AT02753134T ATE374777T1 AT E374777 T1 ATE374777 T1 AT E374777T1 AT 02753134 T AT02753134 T AT 02753134T AT 02753134 T AT02753134 T AT 02753134T AT E374777 T1 ATE374777 T1 AT E374777T1
Authority
AT
Austria
Prior art keywords
analogue
antitumoral compounds
antitumoral
compounds
ecteinascidin
Prior art date
Application number
AT02753134T
Other languages
English (en)
Inventor
Valentin Martinez
Pilar Gallego
Carmen Cuevas
Simon Munt
Ignacio Manzanares
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE374777T1 publication Critical patent/ATE374777T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT02753134T 2001-08-07 2002-08-06 Analoga als antitumorale verbindungen ATE374777T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119243.4A GB0119243D0 (en) 2001-08-07 2001-08-07 Antitumoral analogs of ET-743

Publications (1)

Publication Number Publication Date
ATE374777T1 true ATE374777T1 (de) 2007-10-15

Family

ID=9919954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753134T ATE374777T1 (de) 2001-08-07 2002-08-06 Analoga als antitumorale verbindungen

Country Status (23)

Country Link
US (1) US7763615B2 (de)
EP (3) EP1414828B9 (de)
JP (2) JP4684552B2 (de)
KR (1) KR20040032150A (de)
CN (1) CN100334094C (de)
AT (1) ATE374777T1 (de)
AU (1) AU2002313540B2 (de)
CA (1) CA2455768C (de)
CY (1) CY1107830T1 (de)
DE (1) DE60222775T2 (de)
DK (1) DK1414828T3 (de)
ES (1) ES2294151T3 (de)
GB (1) GB0119243D0 (de)
HK (1) HK1065786A1 (de)
HU (1) HU229779B1 (de)
IL (2) IL160051A0 (de)
MX (1) MXPA04001240A (de)
NO (1) NO337476B1 (de)
NZ (1) NZ530837A (de)
PL (1) PL218295B1 (de)
PT (1) PT1414828E (de)
RU (1) RU2283842C2 (de)
WO (1) WO2003014127A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
ES2523580T3 (es) 2008-01-11 2014-11-27 Albany Molecular Research, Inc. Piridoindoles substituidos con (1-Azinona)
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
CN107033164A (zh) * 2010-05-25 2017-08-11 法马马有限公司 制备海鞘素化合物的合成方法
KR20170096224A (ko) * 2010-11-12 2017-08-23 파르마 마르 에스.에이. 항종양 알칼로이드를 이용한 병용요법
CN103229503B (zh) 2010-11-26 2016-06-29 日本电气株式会社 图像编码设备、图像解码设备、图像编码方法、图像解码方法和程序
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
AU2020342483A1 (en) 2019-09-03 2022-04-14 Pharma Mar, S.A. Lurbinectedin in the treatment of malignant mesothelioma
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
CA3158733A1 (en) * 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
WO2021228414A1 (en) 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
MA56827B2 (fr) 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
PE20230785A1 (es) 2020-04-21 2023-05-11 Pharma Mar Sa Conjugados de anticuerpos de farmacos
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
JP2023541010A (ja) 2020-09-04 2023-09-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジンと免疫チェックポイント阻害剤との組合せ
WO2022101255A1 (en) 2020-11-10 2022-05-19 Pharma Mar, S.A. Lurbinectedin and irinotecan combinations
WO2023031960A1 (en) * 2021-08-31 2023-03-09 Natco Pharma Limited Novel crystalline polymorph of lurbinectedin and improved process for the preparation of lurbinectedin
EP4430075A1 (de) 2021-11-08 2024-09-18 Pharma Mar S.A. Kombinationen aus lurbinectedin und atezolizumab
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
CN115304619A (zh) * 2022-04-08 2022-11-08 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2024188978A1 (en) 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
WO1987007610A2 (en) 1986-06-09 1987-12-17 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
WO1999051238A1 (en) * 1998-04-06 1999-10-14 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
JP4583598B2 (ja) 1998-05-11 2010-11-17 ファルマ・マール・ソシエダード・アノニマ エクテイナシジン７４３の代謝産物
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US6686470B2 (en) * 2000-01-19 2004-02-03 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
BRPI0110024B8 (pt) 2000-04-12 2021-05-25 Pharma Mar Sa derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
IL160051A (en) 2012-01-31
NZ530837A (en) 2005-07-29
KR20040032150A (ko) 2004-04-14
PT1414828E (pt) 2007-12-27
DK1414828T3 (da) 2008-02-04
IL160051A0 (en) 2004-06-20
EP1414828B1 (de) 2007-10-03
MXPA04001240A (es) 2004-06-03
RU2004106617A (ru) 2005-04-10
ES2294151T3 (es) 2008-04-01
EP2270018A1 (de) 2011-01-05
CN1564822A (zh) 2005-01-12
HUP0401174A3 (en) 2005-12-28
NO337476B1 (no) 2016-04-18
DE60222775D1 (de) 2007-11-15
HK1065786A1 (en) 2005-03-04
PL218295B1 (pl) 2014-11-28
WO2003014127A1 (en) 2003-02-20
GB0119243D0 (en) 2001-10-03
JP2011026331A (ja) 2011-02-10
US20060128711A1 (en) 2006-06-15
CA2455768A1 (en) 2003-02-20
DE60222775T2 (de) 2008-07-17
PL367940A1 (en) 2005-03-07
CY1107830T1 (el) 2013-06-19
EP1414828A1 (de) 2004-05-06
HUP0401174A2 (hu) 2005-09-28
EP1806349A1 (de) 2007-07-11
AU2002313540B2 (en) 2008-05-22
JP2005501093A (ja) 2005-01-13
JP4684552B2 (ja) 2011-05-18
US7763615B2 (en) 2010-07-27
EP1414828B9 (de) 2008-02-20
HU229779B1 (en) 2014-07-28
NO20040961L (no) 2004-03-05
RU2283842C2 (ru) 2006-09-20
CN100334094C (zh) 2007-08-29
CA2455768C (en) 2011-10-11

Similar Documents

Publication Publication Date Title
ATE374777T1 (de) Analoga als antitumorale verbindungen
ES2176212T3 (es) Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.
DE60234690D1 (de) Neue verbindungen als entzündungshemmende, immunmodulierende und antiproliferative mittel
NO20021358L (no) Alkylendiamin-substituerte heterocykler
DE69232665D1 (de) Neue 4-arylpiperazine und 4-arylpiperidine
ECSP044997A (es) DERIVADOS SUSTITUIDOS DEL INDENO [1,2-c] ISOQUINOLINA
DE69724777D1 (de) Pentafluorobenzensulfonamiden und analoge
DK1385514T3 (da) Spiroinden- og spiroindanforbindelser
ATE246196T1 (de) Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
DK1273299T3 (da) Minoxidilinindeholdende praparater
NO20051282L (no) Antitumorale analoger av lamellariner.
DK0660822T3 (da) Cykliske benzylamino-, benzylamido- og benzylimidoderivater som antipsykotiske midler
ATE422531T1 (de) Organische verbindungen
DE60236623D1 (de) Amorphe substanz eines tricyclischen triazolobenzazepinderivats
DK0878195T3 (da) Anvendelse af en 2-aroyl-3-arylbenzo(b)thiophenforbindelse til reduktion af fibrinogenniveauerne
MX9302644A (es) Nuevos enantiomeros derivados de (s)-2-amino-2-(3-4-diclorobencil)-1-propanol-
DE69434010D1 (de) C7-Taxan-Derivate und diese enthaltende pharmazeutische Zusammenstellungen
AR035699A1 (es) Asociacion de al menos un derivado de piridoindolona, composicion farmaceutica que comprende al menos un derivado de piridoindolona y kit para el tratamiento de la proliferacion de celulas tumorales
ECSP972237A (es) Derivados de 6,5 heterobiciclicos sustituidos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414828

Country of ref document: EP